Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials

Figure 4

Forest plot of the risk of GMIs in the 15 mg and 5 mg dose groups compared with that in the control group at 26, 52, and 104 weeks. CI: confidence interval; M-H: Mantel-Haenszel.